We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Low-Affinity, Use-Dependent NMDA Receptor Antagonist AR-R 15896AR: An Update of Progress in Stroke.
- Authors
PALMER, GENE C.; CREGAN, EDWARD F.; BIALOBOK, PAUL; SYDSERFF, SIMON G.; HUDZIK, THOMAS J.; McCARTHY, DENNIS J.
- Abstract
ABSTRACT: Use-dependent N-methyl-d-aspartate (NMDA) receptor antagonists protect neurons from the lethal consequences of excessive stimulation by excitatory amino acids. Clinical development of high-affinity compounds such as MK801 have been limited due to untoward side effects. Toward this end, the lower-affinity use-dependent NMDA antagonists have greater margins of safety and have advanced to clinical trials for stroke, epilepsy, head trauma and chronic neurodegenerative disorders. AR-R 15896AR is currently in Phase II trials for stroke and has been repeatedly demonstrated to afford neuroprotection in a variety of in vivo and in vitro models associated with ischemia/excitotoxic conditions.
- Publication
Annals of the New York Academy of Sciences, 1999, Vol 890, Issue 1, p406
- ISSN
0077-8923
- Publication type
Article
- DOI
10.1111/j.1749-6632.1999.tb08020.x